CANI, ALICE
 Distribuzione geografica
Continente #
NA - Nord America 477
EU - Europa 300
AS - Asia 128
AF - Africa 1
Totale 906
Nazione #
US - Stati Uniti d'America 475
PL - Polonia 190
CN - Cina 53
SG - Singapore 40
IT - Italia 38
UA - Ucraina 21
GB - Regno Unito 14
TR - Turchia 14
DE - Germania 13
VN - Vietnam 8
ID - Indonesia 7
BE - Belgio 6
FI - Finlandia 5
SE - Svezia 5
HK - Hong Kong 3
CA - Canada 2
HU - Ungheria 2
IN - India 2
NO - Norvegia 2
RO - Romania 2
BG - Bulgaria 1
EG - Egitto 1
FR - Francia 1
JP - Giappone 1
Totale 906
Città #
Warsaw 190
Fairfield 62
Houston 50
Chandler 47
Woodbridge 45
Ann Arbor 38
Singapore 33
Ashburn 32
Jacksonville 25
Seattle 24
Wilmington 21
Santa Clara 20
Cambridge 18
Ferrara 13
Nanjing 9
Shanghai 9
Beijing 7
Boardman 7
Izmir 7
Jakarta 7
Princeton 7
Brussels 6
Dong Ket 6
Milan 5
Nanchang 5
Cagliari 4
Dearborn 4
London 4
New York 4
Sant'elena 4
Hebei 3
Shenyang 3
Addison 2
Bremen 2
Changsha 2
Focsani 2
Győr 2
Hanoi 2
Harringay 2
Hong Kong 2
Jinan 2
Los Angeles 2
Roncoferraro 2
Toronto 2
Trondheim 2
Zhengzhou 2
Ankara 1
Bhavnagar 1
Bologna 1
Central District 1
Chengdu 1
Des Moines 1
El Mahalla El Kubra 1
Frankfurt am Main 1
Hangzhou 1
Harbin 1
Helsinki 1
Lanzhou 1
Norwalk 1
Potomac 1
Pune 1
Quzhou 1
Redmond 1
Redwood City 1
San Diego 1
Tappahannock 1
Tianjin 1
Varna 1
Wuhan 1
Xi'an 1
Xian 1
Yellow Springs 1
Totale 773
Nome #
Targeting the PI3K/Akt/mTOR signaling pathway as a new therapeutic strategy for personalized treatments in acute lymphoblastic leukemia 196
Triple Akt inhibition as a new therapeutic strategy in T-cell acute lymphoblastic leukemia 154
miR-199a-3p Modulates MTOR and PAK4 Pathways and Inhibits Tumor Growth in a Hepatocellular Carcinoma Transgenic Mouse Model 153
Epstein-Barr virus-specific antibody response in cerebrospinal fluid and serum of patients with multiple sclerosis 139
Targeting the PI3K/Akt/mTOR signaling pathway in B-precursor acute lymphoblastic leukemia and its therapeutic potential. 135
Quantification of CSF and serum levels and intrathecal synthesis of anti-EBV antibodies in patients with multiple sclerosis and with other neurological disorders. 85
Activity of the novel mTOR inhibitor Torin-2 in B-precursor acute lymphoblastic leukemia and its therapeutic potential to prevent Akt reactivation. 25
Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemia. 21
The AKT Inhibitor MK-2206 is Cytotoxic in Hepatocarcinoma Cells Displaying Hyperphosphorylated AKT-1 and Synergizes with Conventional Chemotherapy 19
Totale 927
Categoria #
all - tutte 4.354
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 4.354


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020124 0 0 0 0 0 22 16 23 14 22 13 14
2020/2021194 14 21 10 13 17 18 14 17 10 37 13 10
2021/202275 1 16 10 0 4 5 3 3 3 6 9 15
2022/2023102 10 7 9 14 15 15 6 7 9 1 7 2
2023/202473 3 5 3 0 5 12 5 16 2 1 6 15
2024/202578 6 7 16 9 40 0 0 0 0 0 0 0
Totale 927